Dose Expansion (B): Following the toxicity and activity profile observed in part A, a tumor-specific cohort expansion study in up to 6 potential disease entities with 20 patients per cohort will be initiated, 3 as IOS-1002 monotherapy and 3 as IOS-1002 + PD-1 combination. Depending on the disease entity and line of treatment, the PD-1 cohort will include PD-1 naïve, pre-exposed and refractory patients, respectively.
10 months ago
Clinical • P1 data • Combination therapy • Metastases
|
B2M (Beta-2-microglobulin) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)